The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

M. Kremer, Joel; J. Bloom, Bradley; C. Breedveld, Ferdinand; Coombs, John; P. Fletcher, Mark; Gruben, David; Krishnaswami, Sriram; Burgos‐Vargas, Rubén; Wilkinson, Bethanie; A. F. Zerbini, Cristiano; H. Zwillich, Samuel

doi:10.1002/art.24567

Public

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Published in Arthritis & Rheumatism • Jun 29, 2009

Authors:

Joel M. Kremer

Bradley J. Bloom

Ferdinand C. Breedveld

Abstract

OBJECTIVE: To determine the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response. METHODS: P...

Subject

Medicine

Rheumatoid arthritis

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!